Health Economics›Acute myeloid leukemia›Maintenance after first-line therapy

Maintenance after first-line therapy

Acute myeloid leukemia · 13 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Gemtuzumab ozogamicin monotherapy Variant #04	—	R 122 454	8d	—	~4.9 mo	—	—	1
Sorafenib monotherapy Variant #04	—	R 37 339	28d	—	—	—	—	1
Azacitidine monotherapy Variant #01	—	R 18 699	28d	—	~8.7 mo	—	—	11
Decitabine monotherapy Variant #01	—	R 10 907	42d	—	~6.7 mo	—	—	3
BDMP-BMP-BAMP-BEVP Variant #01 Partial	—	R 9 766	42d	—	—	—	—	—
POMP Variant #01	—	R 8 725	30d	—	—	—	—	—
Cytarabine and Thioguanine Variant #01	—	R 8 146	14d	—	—	—	—	—
Low-dose Cytarabine monotherapy (LoDAC) Variant #01	—	R 172	28d	—	~5.4 mo	—	—	11
Placebo Partial	—	—	—	~4.2 mo	~8.0 mo	—	—	145
Observation Partial	—	—	—	—	14.8 mo	—	—	—
Azacitidine oral monotherapy Variant #01 Partial	—	—	28d	—	24.7 mo	—	—	—
Panobinostat monotherapy Variant #01 Partial	—	—	21d	—	—	—	—	—
Vorinostat monotherapy Variant #01 Partial	—	—	28d	~3.1 mo	—	~4	—	1

13 of 13 regimens shown